EP1324987A1 - Indazoles a action analogue a l'hormone thyroidienne, leur procede de fabrication et leur utilisation dans des medicaments - Google Patents

Indazoles a action analogue a l'hormone thyroidienne, leur procede de fabrication et leur utilisation dans des medicaments

Info

Publication number
EP1324987A1
EP1324987A1 EP01978337A EP01978337A EP1324987A1 EP 1324987 A1 EP1324987 A1 EP 1324987A1 EP 01978337 A EP01978337 A EP 01978337A EP 01978337 A EP01978337 A EP 01978337A EP 1324987 A1 EP1324987 A1 EP 1324987A1
Authority
EP
European Patent Office
Prior art keywords
alkyl
hydrogen
different
hydroxy
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP01978337A
Other languages
German (de)
English (en)
Inventor
Michael Woltering
Helmut Haning
Gunter Schmidt
Josef Pernerstorfer
Hilmar Bischoff
Axel Kretschmer
Verena Vöhringer
Christiane Faeste
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Bayer AG
Bayer Healthcare AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer AG, Bayer Healthcare AG filed Critical Bayer AG
Publication of EP1324987A1 publication Critical patent/EP1324987A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles

Definitions

  • R 20 and R 21 together represent oxygen, or are each the same or different and represent hydrogen, halogen, hydroxy, (Cj-Cg) alkyl, (C r C 6 ) alkoxy or the radical -NR 15 R 16 and
  • aryl stands for an aromatic radical having preferably 6 to 10 carbon atoms.
  • Preferred aryl groups are phenyl and naphthyl.
  • Cycloalkyl in the context of the invention represents a cycloalkyl group with preferably 3 to 8, 3 to 7 or 3 to 6 carbon atoms. Examples and preferably mentioned are: cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and cycloheptyl.
  • the compounds according to the invention can exist in stereoisomeric forms which are either like image and mirror image (enantiomers) or which are not obtained like image and mirror image (diastereomers).
  • the invention relates both to the enantiomers or diastereomers and to their respective mixtures.
  • the racemic forms can be uniformly standardized into the stereoisomers
  • Z represents CH 2 or in particular oxygen
  • Example 8 ⁇ [ethoxy (oxo) acetyl] amino ⁇ -2,6-dimethylphenoxy) -3- ⁇ ropyl-1H-indazol-1-yl] (oxo) - acetates (Example 8). In addition, 18 mg (40%) of the ethyl - ( ⁇ 3,5-dimethyl-4 - [(3-propyl-1H-indazol-5-yl) oxy] phenyl ⁇ amino) (oxo) acetate (Example 8 a) won.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne de nouveaux dérivés de l'indazole, de formule (I), dans laquelle, Z désigne O, S, CH2, CHF ou CF2, et où R1-R7 ont les significations spécifiées dans la revendication 1, ces dérivés ayant une action analogue à l'hormone thyroïdienne. L'invention concerne en outre leur procédé de fabrication et leur utilisation dans des médicaments.
EP01978337A 2000-09-18 2001-09-05 Indazoles a action analogue a l'hormone thyroidienne, leur procede de fabrication et leur utilisation dans des medicaments Withdrawn EP1324987A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10046029A DE10046029A1 (de) 2000-09-18 2000-09-18 Indazole
DE10046029 2000-09-18
PCT/EP2001/010204 WO2002022586A1 (fr) 2000-09-18 2001-09-05 Indazoles a action analogue a l'hormone thyroidienne, leur procede de fabrication et leur utilisation dans des medicaments

Publications (1)

Publication Number Publication Date
EP1324987A1 true EP1324987A1 (fr) 2003-07-09

Family

ID=7656569

Family Applications (1)

Application Number Title Priority Date Filing Date
EP01978337A Withdrawn EP1324987A1 (fr) 2000-09-18 2001-09-05 Indazoles a action analogue a l'hormone thyroidienne, leur procede de fabrication et leur utilisation dans des medicaments

Country Status (6)

Country Link
US (1) US6608049B2 (fr)
EP (1) EP1324987A1 (fr)
AU (1) AU2002210484A1 (fr)
CA (1) CA2422353A1 (fr)
DE (1) DE10046029A1 (fr)
WO (1) WO2002022586A1 (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2356889C2 (ru) 2003-07-17 2009-05-27 Плекссикон, Инк. Соединения, являющиеся активными по отношению к рецепторам, активируемым пролифератором пероксисом
WO2005051298A2 (fr) * 2003-11-19 2005-06-09 Metabasis Therapeutics, Inc. Nouvelles substances thyromimetiques contenant du phosphore
BRPI0508036A (pt) 2004-02-27 2007-07-17 Hoffmann La Roche derivados fundidos de pirazola
EP1720878A1 (fr) 2004-02-27 2006-11-15 F.Hoffmann-La Roche Ag Derives pyrazolo heteroaryl-condenses
JP2007523937A (ja) 2004-02-27 2007-08-23 エフ．ホフマン−ラ　ロシュ　アーゲー インダゾール誘導体およびそれを含む医薬組成物
US7026846B1 (en) * 2004-07-09 2006-04-11 Analog Devices, Inc. Synthesizer structures and methods that reduce spurious signals
BRPI0514017A (pt) * 2004-08-03 2008-05-27 Wyeth Corp indazóis úteis no tratamento de doenças cardiovasculares
EP1647549A1 (fr) * 2004-10-14 2006-04-19 Laboratoire Theramex Indazoles, benzisoxazoles et benzisothiazoles en tant qu'agents oestrogéniques
US7601847B2 (en) 2004-10-26 2009-10-13 Wyeth Preparation and purification of 4-(indazol-3-yl)phenols
CA2606498C (fr) * 2005-05-26 2016-08-09 Metabasis Therapeutics, Inc. Nouvelles substances thyromimetiques contenant de l'acide phosphinique
US20090232879A1 (en) 2005-05-26 2009-09-17 Metabasis Therapeutics, Inc. Thyromimetics for the Treatment of Fatty Liver Diseases
US20060292194A1 (en) * 2005-06-24 2006-12-28 Thomas Lavin Treatment for burns and adipose deposits using thyroid hormone compound in a human
GB0513692D0 (en) * 2005-07-04 2005-08-10 Karobio Ab Novel pharmaceutical compositions
MX2008002588A (es) 2005-08-25 2008-03-18 Hoffmann La Roche Inhibidores de p38-map-cinasa y los metodos para utilizarlos.
CA2655913A1 (fr) * 2006-06-28 2008-01-03 Sanwa Kagaku Kenkyusho Co., Ltd. Nouveau derive heterocyclique bicyclique a 5-6 systemes et son utilisation pharmaceutique
TWI365185B (en) 2008-07-24 2012-06-01 Lilly Co Eli Amidophenoxyindazoles useful as inhibitors of c-met
JOP20190024A1 (ar) 2016-08-26 2019-02-19 Gilead Sciences Inc مركبات بيروليزين بها استبدال واستخداماتها
WO2018094265A2 (fr) 2016-11-21 2018-05-24 Viking Therapeutics, Inc. Méthodes de traitement de glycogénose
BR112019025659A2 (pt) 2017-06-05 2020-08-25 Viking Therapeutics, Inc. composições para o tratamento de fibrose
US10836769B2 (en) 2018-02-26 2020-11-17 Gilead Sciences, Inc. Substituted pyrrolizine compounds and uses thereof
CA3094167A1 (fr) 2018-03-22 2019-09-26 Viking Therapeutics, Inc. Formes cristallines et procedes de production de formes cristallines d'un compose

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2032171A1 (de) * 1970-06-30 1972-01-13 Agfa Gevaert AG, 5090 Leverkusen Lichtempfindliches farbfotografisches Material
GB8501372D0 (en) 1985-01-18 1985-02-20 Smith Kline French Lab Chemical compounds
DK0580550T3 (da) 1992-07-21 1998-02-02 Ciba Geigy Ag Oxamidsyrederivater som hypercholesterolæmiske midler
US6266622B1 (en) 1995-12-13 2001-07-24 Regents Of The University Of California Nuclear receptor ligands and ligand binding domains
US5883294A (en) 1997-06-18 1999-03-16 The Regeants Of The University Of California Selective thyroid hormone analogs
DE19830431A1 (de) * 1998-07-08 2000-01-13 Hoechst Marion Roussel De Gmbh Sulfonylamino-carbonsäure-N-arylamide als Guanylatcyclase-Aktivatoren
CN1314893A (zh) * 1998-07-23 2001-09-26 史密丝克莱恩比彻姆公司 Il－8受体拮抗剂
YU63301A (sh) 1999-03-01 2004-09-03 Pfizer Products Inc. Oksaminske kiseline i njihovi derivati kao ligandi tiroidnog receptora
CO5160290A1 (es) 1999-03-29 2002-05-30 Novartis Ag Derivados de acido fenoxifeniloxamico sustituido .
YU54202A (sh) * 2000-01-18 2006-01-16 Agouron Pharmaceuticals Inc. Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0222586A1 *

Also Published As

Publication number Publication date
US6608049B2 (en) 2003-08-19
AU2002210484A1 (en) 2002-03-26
WO2002022586A1 (fr) 2002-03-21
CA2422353A1 (fr) 2003-03-14
DE10046029A1 (de) 2002-03-28
US20020193610A1 (en) 2002-12-19

Similar Documents

Publication Publication Date Title
EP1324987A1 (fr) Indazoles a action analogue a l'hormone thyroidienne, leur procede de fabrication et leur utilisation dans des medicaments
EP1347959A1 (fr) Derives de l'indole utilises comme ligands de recepteurs de la thyroide
AT390732B (de) Pharmazeutika enthaltend pyrazole
DE69815008T2 (de) Alfa-substituierte Phenylpropionsäurederivate und diese enthaltende Arzneimittel
DE69021501T2 (de) Anti-entzündende 4-aminophenol-derivate.
DE60210784T2 (de) Orale antidiabetische wirkstoffe
CH616923A5 (fr)
DE69429591T2 (de) Therapeutisch wirksame Verbindungen
EP1286957B1 (fr) Derives de diphenylmethane
EP1583743A1 (fr) Dérivés d'indol-phenylsulfonamide utilisés comme composes activant le récepteur ppar-delta
DE2363052A1 (de) 3-phenyl-3-aminoalkyl-2,6-dioxo-tetraund -hexahydropyridine, verfahren zu ihrer herstellung und ihre verwendung in pharmazeutischen zubereitungen
EP0243903A1 (fr) 1-(Oméga[bis-(phényl)alcoxy]-alcoyl) -4-alcénylpipérazines et -4-(alcynyl)-pipérazines respectivement éventuellement substituées, leur procédé de préparation et médicaments qui les contiennent
EP1268422A1 (fr) Indoles pour le traitement de maladies pouvant etre traitees a l'aide d'hormones thyroidiennes
DE3309596A1 (de) 2-substituierte 1-(3'-aminoalkyl)-1,2,3,4-tetrahydro-ss-carboline, ihre herstellung und verwendung als arzneimittel
DE10115408A1 (de) Benzofuran-Derivate
EP0657166A1 (fr) Composition contenant un quinixaline et un nucléoside
DE69228042T2 (de) Naphthamide, Verfahren zur Herstellung und ihre therapeutische Anwendung
WO2002072539A1 (fr) Derives de diphenyle
DE69311123T2 (de) Cyclische benzylamino-, benzylamido- und benzylimido derivate als antipsychotische wirkstoffe
EP1654227A1 (fr) Derives bicycliques d'indoline-sulfonamides
DE3424586A1 (de) 3-aminocarbonylmethoxy-5-phenyl-pyrazol-verbindungen sowie verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
DE69529807T2 (de) Neue Parabansäure-Derivate als Aldose-Reduktase Inhibitoren
DE10131462A1 (de) Phenol-Derivate
DE69521310T2 (de) Chinolonderivat zur behandlung der harnincontinenz
CH639107A5 (de) Neue acylderivate des hellebrigenins.

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

17P Request for examination filed

Effective date: 20030422

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: BAYER HEALTHCARE AG

RBV Designated contracting states (corrected)

Designated state(s): DE ES FR GB IT

17Q First examination report despatched

Effective date: 20060814

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20061228